Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.

NK cell-based cancer immunotherapy: from basic biology to clinical development

Open access
Liu, Sizhe, Galat, Vasiliy, Galat4, Yekaterina, Lee, Yoo Kyung Annie, Wainwright, Derek, Wu, Jennifer·2021·Journal of Hematology & Oncology

Abstract

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-01014-w

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 151 references

Research works printed but not linked: 1

  1. Li Y, et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018; 23(2): 181–192. · DOI · Paper page

Cited by

See all 689

Metadata

Authors
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J.
Affiliations
  • Northwestern University (US)
  • Emory University (US)
Corresponding author
Wu, Jennifer
Venue
Journal of Hematology & Oncology
Published
2021-01-06
Volume
14
Issue
1
Pages
7-7
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3120414804
Cited by
689
References
151
Citations by year
2026: 61 · 2025: 158 · 2024: 161 · 2023: 139 · 2022: 122 · 2021: 48
FWCI
12.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Cancer Institute (1R01CA208246, 1R01CA204021, 1R01CA212409)
  • U.S. Department of Defense (W81XWH-15-1-0406)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
natural killer cells, NK cell activation, NK cell receptors, NK cell engineering, adoptive immunotherapy
MeSH terms
Animals, Clinical Trials as Topic, Humans, Immunologic Surveillance, Killer Cells, Natural, Lymphocyte Activation, Neoplasms, Immunotherapy, Adoptive, Tumor Escape

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NK cell-based cancer immunotherapy: from basic biology to clinical development. https://app.cochat.ai/papers/10.1186/s13045-020-01014-w
The paper
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021). NK cell-based cancer immunotherapy: from basic biology to clinical development. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-01014-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.